Having 2B outstanding shares doesn't help but you never know how this will fly if a major pharma likes what it sees and backs it, especially if hemaxellerate proves multi pronged in reversing/curing diseases efficiently and cheaper than traditional remedies. Plus, it doesn't take a lot of cash to buy back shares if it remains in the pennies to reduce O/S.